{"id":"tnf-blocker","safety":{"commonSideEffects":[{"rate":null,"effect":"Increased infection risk (including tuberculosis)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Demyelinating disease (rare)"}]},"_chembl":{"chemblId":"CHEMBL1402326","moleculeType":"Small molecule","molecularWeight":"540.13"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TNF is a pro-inflammatory cytokine central to inflammatory and autoimmune diseases. TNF blockers work by binding to and neutralizing TNF or blocking its receptors (TNFR1/TNFR2), thereby suppressing the inflammatory cascade. This reduces immune activation, decreases recruitment of inflammatory cells, and alleviates symptoms in conditions driven by excessive TNF signaling.","oneSentence":"TNF blockers inhibit tumor necrosis factor (TNF), a key inflammatory cytokine, to reduce inflammation and immune-mediated tissue damage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:13:01.028Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriasis"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT07477795","phase":"PHASE2","title":"Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04-01","conditions":"Takayasu Arteritis, Large Vessel Vasculitis","enrollment":52},{"nctId":"NCT07491913","phase":"NA","title":"Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission","status":"RECRUITING","sponsor":"Marmara University","startDate":"2025-06-15","conditions":"Takayasu Arteritis","enrollment":40},{"nctId":"NCT06654882","phase":"PHASE3","title":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-09","conditions":"Polyarticular Course Juvenile Idiopathic Arthritis (JIA)","enrollment":400},{"nctId":"NCT07453628","phase":"","title":"Association of Erectile Dysfunction With Neuropathic Pain, Disease Activity, and Functional Status in Male Patients With Axial Spondyloarthritis: A Cross-Sectional Observational Study","status":"COMPLETED","sponsor":"Altuğ Güner","startDate":"2021-02-03","conditions":"Ankylosing Spondylitis, Sexual Dysfunction","enrollment":90},{"nctId":"NCT00385086","phase":"PHASE3","title":"Lumbar Spinal Fibrosis and TNF Alpha Inhibition","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2007-02","conditions":"Post Operative Sciatica by Lumbar Spinal Fibrosis","enrollment":38},{"nctId":"NCT04066348","phase":"PHASE2","title":"TNF-α Treatment of Blast-Induced Tinnitus","status":"RECRUITING","sponsor":"Wayne State University","startDate":"2022-07-01","conditions":"Tinnitus, Noise Induced","enrollment":88},{"nctId":"NCT06905288","phase":"","title":"Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-02","conditions":"Ankylosing Spondylitis","enrollment":70},{"nctId":"NCT06712628","phase":"","title":"A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-11-07","conditions":"Moderate to Severe Rheumatoid Arthritis","enrollment":678},{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT07293910","phase":"PHASE2","title":"Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Tanta University","startDate":"2026-02-15","conditions":"HELICOBACTER PYLORI INFECTIONS, Helicobacter Infection, Helicobacter Pylori Gastrointestinal Tract Infection","enrollment":66},{"nctId":"NCT06440629","phase":"PHASE4","title":"Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)","status":"RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2024-08-20","conditions":"Rheumatoid Arthritis","enrollment":350},{"nctId":"NCT07386587","phase":"PHASE3","title":"Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis","status":"ENROLLING_BY_INVITATION","sponsor":"University of Child Health Sciences and Children's Hospital, Lahore","startDate":"2026-01-27","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT02714881","phase":"","title":"Lipids, Inflammation, and CV Risk in RA","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-10-17","conditions":"Rheumatoid Arthritis, Cardiovascular Disease","enrollment":74},{"nctId":"NCT07117344","phase":"","title":"Biomarkers in Ankylosing Spondylitis","status":"RECRUITING","sponsor":"Kirsehir Ahi Evran Universitesi","startDate":"2026-01-15","conditions":"Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA)","enrollment":160},{"nctId":"NCT05814627","phase":"PHASE3","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-15","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT05590455","phase":"PHASE2","title":"Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-04-11","conditions":"Tuberculous Meningitis, HIV I Infection","enrollment":130},{"nctId":"NCT03739853","phase":"PHASE4","title":"Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-05-14","conditions":"Psoriatic Arthritis","enrollment":192},{"nctId":"NCT01022749","phase":"PHASE3","title":"Efficacy Safety Study of Flu Vaccine in Immunodepression Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-09","conditions":"Inflammatory Bowel Disease (IBD)","enrollment":228},{"nctId":"NCT03123120","phase":"PHASE2","title":"A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-06-07","conditions":"Colitis, Ulcerative","enrollment":22},{"nctId":"NCT05428488","phase":"PHASE3","title":"Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2022-11-28","conditions":"Rheumatoid Arthritis","enrollment":220},{"nctId":"NCT07181694","phase":"PHASE1","title":"A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects","status":"RECRUITING","sponsor":"Biocad","startDate":"2025-03-12","conditions":"Healthy Adult Male","enrollment":444},{"nctId":"NCT07198113","phase":"","title":"COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)","status":"NOT_YET_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-11-01","conditions":"Ulcerative Colitis, Pediatric, Inflammatory Bowel Diseases, Crohn Disease","enrollment":1100},{"nctId":"NCT07166315","phase":"","title":"Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor","status":"RECRUITING","sponsor":"Adelphi Real World","startDate":"2025-07-07","conditions":"Axial Spondylarthritis (axSpA), Psoriatic Arthritis (PsA)","enrollment":700},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT06418529","phase":"","title":"A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-05-15","conditions":"Rheumatoid Arthritis","enrollment":21340},{"nctId":"NCT03915964","phase":"PHASE4","title":"A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-25","conditions":"Rheumatoid Arthritis","enrollment":2663},{"nctId":"NCT03358693","phase":"","title":"Molecular Signatures in Inflammatory Skin Disease","status":"RECRUITING","sponsor":"Prof. Dr. Stephan Weidinger","startDate":"2017-01-20","conditions":"Atopic Dermatitis, Psoriasis","enrollment":300},{"nctId":"NCT04086745","phase":"PHASE4","title":"A Study of Baricitinib in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-14","conditions":"Rheumatoid Arthritis","enrollment":1317},{"nctId":"NCT07041112","phase":"","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","status":"COMPLETED","sponsor":"Juan Ruano Ruiz","startDate":"2012-01-01","conditions":"Psoriasis, Psoriatic Arthritis (PsA), Cardiovascular Risk Factors","enrollment":1000},{"nctId":"NCT05080218","phase":"PHASE4","title":"COVID-19 VaccinE Response in Rheumatology Patients","status":"COMPLETED","sponsor":"Jeffrey Curtis","startDate":"2021-11-15","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis","enrollment":841},{"nctId":"NCT06281106","phase":"PHASE2, PHASE3","title":"TYK2 Inhibition in Paradoxical Psoriasis","status":"TERMINATED","sponsor":"Prof Curdin Conrad","startDate":"2024-06-20","conditions":"Psoriasis","enrollment":2},{"nctId":"NCT06653634","phase":"PHASE4","title":"Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-10-24","conditions":"Juvenile Idiopathic Arthritis","enrollment":150},{"nctId":"NCT01086059","phase":"","title":"OTIS Humira Pregnancy Registry","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2003-11","conditions":"Crohn's Disease, Rheumatoid Arthritis","enrollment":944},{"nctId":"NCT05350644","phase":"","title":"Inflammatory Bowel Disease(IBD), Treatment Response","status":"TERMINATED","sponsor":"University of Southern Denmark","startDate":"2022-02-08","conditions":"Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease","enrollment":2},{"nctId":"NCT03445845","phase":"PHASE4","title":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-12-14","conditions":"Axial Spondyloarthritis","enrollment":300},{"nctId":"NCT04347798","phase":"","title":"IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2020-11-01","conditions":"Covid-19 Infection, Rheumatoid Arthritis, Psoriatic Arthritis","enrollment":773},{"nctId":"NCT06601595","phase":"","title":"Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor (TNF) Inhibitors Treatment in Assiut University Hospital","status":"NOT_YET_RECRUITING","sponsor":"Mohamed Nasr","startDate":"2024-10","conditions":"Inflammatory Bowel Disease (IBD), Spondylarthropathies, TNF-alpha Inhibitors","enrollment":100},{"nctId":"NCT06563635","phase":"","title":"Frequency of Tuberculosis in Psoriasis Patients","status":"COMPLETED","sponsor":"Bezmialem Vakif University","startDate":"2023-05-01","conditions":"Psoriasis Vulgaris, Tuberculosis","enrollment":719},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT01242488","phase":"PHASE2","title":"Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2010-11","conditions":"Rheumatoid Arthritis","enrollment":221},{"nctId":"NCT02450513","phase":"","title":"Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2012-03","conditions":"Crohn's Disease","enrollment":30},{"nctId":"NCT03652961","phase":"PHASE4","title":"Rheumatoid Arthritis Memory B Cells and Abatacept","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-06-02","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT04731831","phase":"","title":"Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.","status":"RECRUITING","sponsor":"Aalborg University Hospital","startDate":"2020-08-01","conditions":"Arthritis, Rheumatoid, Arthritis, Psoriatic, Spondylitis, Ankylosing","enrollment":120},{"nctId":"NCT06400589","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease","status":"SUSPENDED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2024-05-01","conditions":"Dry Eye","enrollment":750},{"nctId":"NCT04721821","phase":"","title":"Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-01-22","conditions":"Arthritis Rheumatoid","enrollment":7807},{"nctId":"NCT06299631","phase":"","title":"Endoscopic Relapse Risks Evaluation After Ileocolic Resection for Crohn's Disease","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2015-01","conditions":"Crohn's Disease","enrollment":133},{"nctId":"NCT03839862","phase":"","title":"Faecal Analyses in Spondyloarthritis Therapy","status":"RECRUITING","sponsor":"Region Skane","startDate":"2019-01-01","conditions":"Spondyloarthropathies, Ankylosing Spondylitis","enrollment":50},{"nctId":"NCT05447182","phase":"","title":"People-Powered Medicine (PPM): Rheumatoid Arthritis Non-responders to Biologic Therapies (RANT)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-06","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT05115903","phase":"PHASE4","title":"Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-12-01","conditions":"Axial Spondyloarthritis","enrollment":15},{"nctId":"NCT06177405","phase":"","title":"Predicting the Response of Patients With Rheumatoid Arthritis to Treatment With Genetically Engineered Biological Drugs and Janus (JAK) Kinase Inhibitors","status":"COMPLETED","sponsor":"Institute of Biomedical Chemistry, Russia","startDate":"2021-01-15","conditions":"Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT05702879","phase":"","title":"Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success","status":"UNKNOWN","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-09-06","conditions":"Ulcerative Colitis","enrollment":240},{"nctId":"NCT06109961","phase":"PHASE1, PHASE2","title":"Hyperbaric Oxygen Therapy for Perianal Fistulizing Crohn's Disease Not Responsive or Intolerant to Conventional Care: HYPNOTIC Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2024-01","conditions":"Inflammatory Bowel Disease (IBD)","enrollment":40},{"nctId":"NCT00116272","phase":"","title":"Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-04","conditions":"Pregnancy","enrollment":830},{"nctId":"NCT03293784","phase":"PHASE1","title":"TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2017-10-16","conditions":"Melanoma","enrollment":33},{"nctId":"NCT04255134","phase":"PHASE4","title":"Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)","status":"COMPLETED","sponsor":"St George's, University of London","startDate":"2020-09-07","conditions":"Rheumatoid Arthritis","enrollment":18},{"nctId":"NCT03619876","phase":"PHASE4","title":"Effects of Abatacept on Myocarditis in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Columbia University","startDate":"2019-07-10","conditions":"Rheumatoid Arthritis, Myocardial Inflammation","enrollment":11},{"nctId":"NCT00042406","phase":"PHASE2, PHASE3","title":"Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker","status":"TERMINATED","sponsor":"Genmab","startDate":"2002-03-04","conditions":"Rheumatoid Arthritis","enrollment":83},{"nctId":"NCT01828190","phase":"NA","title":"The Influence of Hyperbaric Oxygen in Patients With Perianal Crohn's Disease Already Treated With TNF Alpha Blockers Treated With TNF Alpha Blockers","status":"COMPLETED","sponsor":"Assaf-Harofeh Medical Center","startDate":"2013-03","conditions":"Crohn's Disease, Perianal Fistulas","enrollment":50},{"nctId":"NCT05767814","phase":"","title":"Optimization of Psoriatic and Seronegative Rheumatoid Arthritis Patients Selection and Treatment Outcomes of Biologic Therapies.","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2019-10-03","conditions":"Psoriatic Arthritis, Rheumatoid Arthritis","enrollment":135},{"nctId":"NCT05182203","phase":"","title":"Safety and Retention Rate of the JAK and TNF Inhibitors in Rheumatoid Arthritis: a Real-life Experience","status":"COMPLETED","sponsor":"Tuen Mun Hospital","startDate":"2022-03-01","conditions":"Rheumatoid Arthritis, Drug Use","enrollment":1732},{"nctId":"NCT05651373","phase":"","title":"The Clinical Features and Pregnancy Outcomes of RA Patients","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2021-07-30","conditions":"Rheumatoid Arthritis, Pregnancy Related","enrollment":100},{"nctId":"NCT02374021","phase":"PHASE4","title":"Treatments Against RA and Effect on FDG-PET/CT","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-07","conditions":"Arthritis, Rheumatoid","enrollment":159},{"nctId":"NCT03589833","phase":"PHASE4","title":"Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2019-05-14","conditions":"Arthritis, Rheumatoid","enrollment":504},{"nctId":"NCT05567380","phase":"","title":"Comparative Study of Janus Kinase (JAK) Inhibitors Vs Tumor Necrosis Factor (TNF) Inhibitors in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-10","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT03351647","phase":"","title":"Predictive Factors of Clinical Response to Ustekinumab in Active Crohn's Disease","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-02-14","conditions":"Crohn Disease","enrollment":18},{"nctId":"NCT03331393","phase":"","title":"The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-03-16","conditions":"Rheumatoid Arthritis","enrollment":265},{"nctId":"NCT04798287","phase":"","title":"Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-03-10","conditions":"Rheumatoid Arthritis","enrollment":105711},{"nctId":"NCT03033095","phase":"NA","title":"Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysis of Serum Biomarkers","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2016-07","conditions":"Spondylitis, Ankylosing","enrollment":50},{"nctId":"NCT05405465","phase":"","title":"Effectiveness of Golimumab in Patients With Ulcerative Colitis: Results of a Real-life Study in Switzerland","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2018-01-01","conditions":"Ulcerative Colitis, Flare Up, Symptom","enrollment":103},{"nctId":"NCT04399382","phase":"","title":"A Clinical Study to Evaluate the Efficacy of Biologics in SpA","status":"UNKNOWN","sponsor":"The University of Hong Kong-Shenzhen Hospital","startDate":"2022-01-12","conditions":"Spondyloarthritis (SpA)","enrollment":40},{"nctId":"NCT03419143","phase":"","title":"Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-03-02","conditions":"Psoriatic Arthritis (PsA)","enrollment":190},{"nctId":"NCT03449758","phase":"PHASE4","title":"Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-05","conditions":"Rheumatoid Arthritis","enrollment":84},{"nctId":"NCT01881308","phase":"PHASE4","title":"Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Diakonhjemmet Hospital","startDate":"2013-06-17","conditions":"Rheumatoid Arthritis","enrollment":320},{"nctId":"NCT04370236","phase":"PHASE2, PHASE3","title":"INB03 for the Treatment of Pulmonary Complications From COVID-19","status":"TERMINATED","sponsor":"Inmune Bio, Inc.","startDate":"2020-10-21","conditions":"COVID-19","enrollment":79},{"nctId":"NCT03663829","phase":"","title":"Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-10-04","conditions":"Rheumatoid Arthritis","enrollment":2052},{"nctId":"NCT04772248","phase":"","title":"Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-02-22","conditions":"Rheumatoid Arthritis","enrollment":105711},{"nctId":"NCT05164198","phase":"PHASE4","title":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2022-01-15","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":448},{"nctId":"NCT05153200","phase":"PHASE4","title":"Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.","status":"UNKNOWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2022-01","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT02136069","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-12-24","conditions":"Ulcerative Colitis","enrollment":397},{"nctId":"NCT04729296","phase":"PHASE2","title":"Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D","status":"WITHDRAWN","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 1","enrollment":""},{"nctId":"NCT04529902","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - TNFi vs Abatacept","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-08-17","conditions":"Rheumatoid Arthritis","enrollment":63013},{"nctId":"NCT00789308","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07-11","conditions":"Diabetes Mellitus, Type I","enrollment":24},{"nctId":"NCT02165215","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-08-12","conditions":"Colitis, Ulcerative","enrollment":359},{"nctId":"NCT02092467","phase":"PHASE4","title":"Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03-14","conditions":"Arthritis, Rheumatoid","enrollment":4372},{"nctId":"NCT02100696","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-05-21","conditions":"Ulcerative Colitis","enrollment":609},{"nctId":"NCT02171429","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-11-14","conditions":"Ulcerative Colitis","enrollment":358},{"nctId":"NCT02163759","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-11-04","conditions":"Ulcerative Colitis","enrollment":358},{"nctId":"NCT04973787","phase":"","title":"The Role of Microbiome on Biological Therapy Efficacy in axSpA and RA","status":"UNKNOWN","sponsor":"Universidade Nova de Lisboa","startDate":"2020-08-01","conditions":"Axial Spondyloarthritis, Arthritis, Rheumatoid","enrollment":90},{"nctId":"NCT04953871","phase":"PHASE4","title":"Enthesitis Assessment Before and After Anti-Tumor Necrosis Factor Treatment in Spondyloarthritis","status":"COMPLETED","sponsor":"Gunay ER","startDate":"2017-01","conditions":"Spondyloarthritis, Enthesitis, Anti-Tumor Necrosis Factor Drugs","enrollment":31},{"nctId":"NCT02015520","phase":"PHASE2","title":"Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2012-06","conditions":"Rheumatoid Arthritis","enrollment":143},{"nctId":"NCT03561649","phase":"NA","title":"Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive SpA","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2018-06-14","conditions":"Spondylitis, Ankylosing","enrollment":50},{"nctId":"NCT01764321","phase":"","title":"Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-12","conditions":"Rheumatoid Arthritis","enrollment":1723},{"nctId":"NCT03802214","phase":"","title":"Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy","status":"TERMINATED","sponsor":"Stanford University","startDate":"2020-10-29","conditions":"Ulcerative Colitis","enrollment":1},{"nctId":"NCT01548768","phase":"PHASE4","title":"RHYTHM (Formerly Escape II Myocardium)","status":"COMPLETED","sponsor":"Columbia University","startDate":"2011-10-10","conditions":"Rheumatoid Arthritis","enrollment":149},{"nctId":"NCT02353780","phase":"PHASE4","title":"Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept","status":"TERMINATED","sponsor":"Dr. Larry W. Moreland","startDate":"2015-03","conditions":"Rheumatoid Arthritis (RA)","enrollment":10},{"nctId":"NCT04115423","phase":"","title":"A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2020-04-01","conditions":"Infection, Rheumatoid Arthritis","enrollment":9508},{"nctId":"NCT00311246","phase":"PHASE2","title":"Trial of Adalimumab in Progressive Sarcoidosis","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2006-04","conditions":"Sarcoidosis","enrollment":11},{"nctId":"NCT02983227","phase":"PHASE2","title":"A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-11-30","conditions":"Rheumatoid Arthritis","enrollment":496},{"nctId":"NCT02696798","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-04-12","conditions":"Spondyloarthritis","enrollment":316},{"nctId":"NCT02960035","phase":"PHASE4","title":"A Study of the MASEI in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-04","conditions":"Spondyloarthropathy","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"TNF blocker","genericName":"TNF blocker","companyName":"Centre Hospitalier Universitaire de Saint Etienne","companyId":"centre-hospitalier-universitaire-de-saint-etienne","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TNF blockers inhibit tumor necrosis factor (TNF), a key inflammatory cytokine, to reduce inflammation and immune-mediated tissue damage. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}